12/12/2025
Riley Children’s Health continues to lead groundbreaking efforts in pediatric endocrinology and diabetes care, blending innovative research with nationally recognized expertise.
Repurposing DFMO for Type 1 Diabetes
Complementing work by Dr. Linda DiMeglio demonstrating DFMO’s safety in newly diagnosed type 1 diabetes patients, Riley clinician-scientist Dr. Emily Sims is leading a pediatric clinical trial further exploring DFMO’s efficacy in preserving beta cell function. Together, these initiatives underscore Riley Children’s endocrinology leadership in advancing therapies that move beyond symptom management toward disease-modifying strategies for type 1 diabetes, offering hope for more effective and lasting treatments for young patients
Delivering Breakthrough Diabetes Therapy
A Riley Children’s patient was the first in the state to receive teplizumab, a breakthrough therapy offering new hope in kids younger than 8 to prevent the onset of stage 3 type 1 diabetes. The therapy aims to protect insulin-producing cells, offering families new hope for improved long-term outcomes and marking a major milestone in pediatric diabetes care. As an ongoing extension of this work, endocrinologists at Riley Children’s co-authored new clinical practice guidelines in 2024 for the use of teplizumab in clinical practice.
Optimizing Continuous Glucose Monitoring for Better Outcomes
Another innovative study at Riley Children’s examines how pediatric patients use continuous glucose monitors (CGMs)—devices that provide real-time glucose readings. Findings revealed variability of real-time CGM alarms and opportunities for better guidance and training on CGMs. This work underscores Riley Children’s commitment to advancing technology-driven care and empowering families to manage diabetes effectively.
Leadership in Pediatric Endocrinology
Beyond research, Riley Children’s celebrates the achievements of Dr. Linda DiMeglio, division chief of pediatric endocrinology and diabetology, who was inducted into the American Pediatric Society (APS) in 2023. This honor recognizes her exceptional contributions to academic pediatrics and her dedication to improving care for children with endocrine disorders. Dr. DiMeglio’s work spans Type 1 diabetes prevention, metabolic bone disease research, and developing international care guidelines—efforts that continue to shape the future of pediatric care.
Learn more about Riley Children’s diabetes and endocrinology achievements in the annual report.
